TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 19nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 21nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 23nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma
US Patent
Topivert Pharma
US Patent
Affinity DataIC50: 25nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair